Galectin Therapeutics Inc (GALT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Galectin Therapeutics Inc (GALT) has a cash flow conversion efficiency ratio of 0.030x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.87 Million) by net assets ($-130.24 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Galectin Therapeutics Inc (GALT) market capitalisation for the company's overall valuation and market capitalisation.
Galectin Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2000–2025)
This chart illustrates how Galectin Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Galectin Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Galectin Therapeutics Inc ranked by their cash flow conversion efficiency. Explore GALT operating cash flow to net income to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Banvit Bandirma Vitaminli Yem Sanayi AS
IS:BANVT
|
-0.067x |
|
CapsoVision, Inc. Common Stock
NASDAQ:CV
|
-0.638x |
|
BLD Plantation Bhd
KLSE:5069
|
-0.051x |
|
KOSES Co.Ltd
KQ:089890
|
0.044x |
|
ZCCM Investments Holdings Plc
PA:MLZAM
|
-0.002x |
|
Beijing Seeyon Internet Software Cp
SHG:688369
|
-0.118x |
|
Wuhan Citms Technology Co Ltd
SHG:688038
|
-0.054x |
|
Gérard Perrier Industrie S.A.
PA:PERR
|
0.163x |
Annual Cash Flow Conversion Efficiency for Galectin Therapeutics Inc (2000–2025)
The table below shows the annual cash flow conversion efficiency of Galectin Therapeutics Inc from 2000 to 2025. View GALT share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-126.19 Million | $-23.88 Million | 0.189x | -53.31% |
| 2024-12-31 | $-103.07 Million | $-41.77 Million | 0.405x | -25.95% |
| 2023-12-31 | $-60.24 Million | $-32.97 Million | 0.547x | -43.27% |
| 2022-12-31 | $-32.19 Million | $-31.06 Million | 0.965x | +110.38% |
| 2021-12-31 | $2.62 Million | $-24.31 Million | -9.292x | -991.22% |
| 2020-12-31 | $24.19 Million | $-20.60 Million | -0.852x | -257.90% |
| 2019-12-31 | $45.59 Million | $-10.85 Million | -0.238x | +83.88% |
| 2018-12-31 | $6.90 Million | $-10.18 Million | -1.476x | +88.92% |
| 2017-12-31 | $1.19 Million | $-15.89 Million | -13.321x | -875.39% |
| 2016-12-31 | $12.02 Million | $-16.41 Million | -1.366x | -101.43% |
| 2015-12-31 | $25.05 Million | $-16.98 Million | -0.678x | -52.64% |
| 2014-12-31 | $27.97 Million | $-12.43 Million | -0.444x | +51.17% |
| 2013-12-31 | $8.23 Million | $-7.48 Million | -0.910x | +3.97% |
| 2012-12-31 | $7.92 Million | $-7.50 Million | -0.947x | +26.61% |
| 2011-12-31 | $4.40 Million | $-5.68 Million | -1.291x | -170.49% |
| 2010-12-31 | $-1.69 Million | $-3.10 Million | 1.831x | +110.44% |
| 2009-12-31 | $-4.47 Million | $-3.89 Million | 0.870x | -91.25% |
| 2008-12-31 | $-469.00K | $-4.67 Million | 9.947x | +430.44% |
| 2007-12-31 | $-2.92 Million | $-5.48 Million | 1.875x | -99.39% |
| 2006-12-31 | $-22.00K | $-6.76 Million | 307.136x | +18060.99% |
| 2005-12-31 | $3.58 Million | $-6.13 Million | -1.710x | -172.85% |
| 2004-12-31 | $10.11 Million | $-6.33 Million | -0.627x | -15.08% |
| 2003-12-31 | $7.62 Million | $-4.15 Million | -0.545x | +70.49% |
| 2002-12-31 | $1.62 Million | $-2.98 Million | -1.845x | -24.69% |
| 2001-12-31 | $1.22 Million | $-1.80 Million | -1.480x | +17.78% |
| 2000-12-31 | $50.00K | $-90.00K | -1.800x | -- |
About Galectin Therapeutics Inc
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhos… Read more